Malaria
Conditions
Interventions
Artesunate Amodiaquine (ASAQ)
Dehydroartemisinine Piperaquine (DHAPQ)
Sponsors
University Cheikh Anta DIOP of Dakar
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects aged over 6 months with the uncomplicated P. falciparum malaria, Parasite density between 1000 and 100000 trophozoites/¿l, Presence of an axillary temperature higher than 37.5° or history of fever during the previous 24 hours, Ability to take oral medication and given her inform consent were included in the study
Exclusion criteria
Exclusion criteria: Patients presenting mono-infestation by another species or mixted infestation, severe vomiting, severe malnutrition, severe signs of malaria (such as severe anemia, convulsion, respiratory distress), women with positive pregnancy test and patients who had a history of allergy to study drugs or not given her inform consent were excluded in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adequate clinical and parasitological response (ACPR) after corrected PCR at day 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| ACPR at days 35 and 42;Parasite and fever clearence time;Incidence of drug related adverse events | — |
Countries
Senegal
Contacts
Public ContactMagatte NDiaye
Focal point of antimalarial drugs resistance in the department of Parasitology
Outcome results
None listed